Scientists have identified a specific protein, known as Miro1, that plays a significant role in the development of type 2 diabetes by interfering with the body’s ability to respond to insulin. The discovery, published in Nature Communications, provides a concrete biological target for future therapies aimed at improving blood sugar control and addresses a long-standing gap in understanding the molecular causes of insulin resistance.
Miro1 Accumulation Impairs Muscle Function
Miro1, or Mitochondrial Rho GTPase1, is located on the outer membrane of mitochondria, the cellular structures responsible for energy production. The research team found that Miro1 levels were significantly higher in the skeletal muscles of individuals with type 2 diabetes compared to those without the condition. This accumulation appears to disrupt the muscles’ ability to respond to insulin, making it difficult for the body to regulate blood sugar effectively.
To verify this connection, the researchers conducted a multi-stage investigation involving laboratory cells, preclinical models, and human participants. In preclinical experiments, scientists removed Miro1 from muscle tissue, which resulted in the restoration of insulin responsiveness. This causal link suggests that excessive Miro1 is not merely a symptom of the disease but a direct contributor to the impairment of muscle function.
The study was led by Dr. John P. Kirwan, the senior author who recently became the executive director of the OU Health Harold Hamm Diabetes Center at the University of Oklahoma. Kirwan conducted the bulk of this research while serving as Vice Provost for Diabetes Programs and holding the Chickasaw Nation Endowed Chair in Diabetes Research at LSU’s Pennington Biomedical Research Center. The first author of the study is doctoral candidate Elizabeth Heintz, who worked in the Integrated Physiology and Molecular Medicine Laboratory at Pennington Biomedical. Christopher Axelrod, the co-corresponding author, has also joined Kirwan at the Harold Hamm Diabetes Center to continue this line of inquiry.
Exercise Reduces Miro1 Levels in Patients
One of the most practical findings from the study is the impact of physical activity on Miro1 levels. In a randomized controlled trial involving participants with obesity and type 2 diabetes, researchers compared the effects of aerobic exercise against standard medical care. The results showed that participants in the exercise group experienced a measurable decline in Miro1 levels within their muscles.
These reductions in Miro1 occurred alongside improvements in insulin sensitivity and the muscles’ capacity to produce energy. The findings suggest that exercise helps the body respond more effectively to insulin, at least in part, by reducing the buildup of this interfering protein. This offers a scientific explanation for why physical activity is so effective in managing the condition and raises the possibility that treatments targeting Miro1 could complement the benefits of exercise.
Dr. Jennifer Rood, Interim Senior Vice Chancellor and Executive Director of Pennington Biomedical, emphasized the importance of this integrated approach. She noted that the research exemplifies the breadth of scientific discovery at the institution, connecting fundamental biological mechanisms with clinical studies and population-based research to inform public health strategies.
Despite the promising results, scientists caution that directly targeting Miro1 for therapeutic use is still in the early stages. The restoration of insulin responsiveness was demonstrated in preclinical models, while the human trial focused on the effects of exercise. Further research is required to establish whether drugs or other interventions that lower Miro1 can produce safe and effective treatments for people with type 2 diabetes.
“Insulin resistance in muscle is at the heart of Type 2 diabetes, and its molecular causes have remained frustratingly unclear. This study, the product of years of work, identifies Miro1 as a key part of the answer. By tracing Miro1 from cells to preclinical models to patients, we show that Miro1 accumulation impairs the muscle’s response to insulin, that removing it causally restores that response in our models, and that exercise reverses its buildup in people. For the field, this is a new therapeutic target. For patients, it deepens our understanding of why exercise is so effective and opens a path toward treatments that could one day complement it,” said Dr. John P. Kirwan.
Kirwan plans to continue investigating these findings at the Harold Hamm Diabetes Center, combining laboratory experiments with human studies to uncover more biological mechanisms responsible for diabetes. The study received funding from several National Institutes of Health institutes, including the National Institute of Diabetes and Digestive and Kidney Diseases, the National Institute on Aging, the National Center for Complementary and Integrative Health, the National Heart, Lung, and Blood Institute, and the National Institute of General Medical Sciences.
Source: ScienceDaily
